New model for intravenous drug administration and blood sampling in the awake rat, designed to increase quality and throughput for in vivo pharmacokinetic analysis.
BACKGROUND
There is a continuing need for increased throughput in the examination of new chemical entities (NCEs) in terms of the pharmacokinetic (PK) parameters. The aim was to validate a new study method designed to improve throughput and reduce inter-animal variability and animal number requirement in routine bioavailability and plasma PK studies of NCEs in awake rats.


METHODS
The design uses a new method for intravenous (iv) administration via the saphenous vein in combination with serial blood sampling via the tail vein. The multiple sampling method was compared with single sampling (decapitation) and the effect on haematocrit (Hct) levels was studied. Direct injection in the saphenous vein was compared to iv administration using an indwelling jugular catheter.


RESULTS
Using structurally different NCEs, it was shown that a combination of direct injection via the saphenous vein and multiple sampling from the tail vein produces comparable plasma concentrations and subsequent PK results to the comparator methods. Furthermore, Hct levels remained within recommended levels using a total blood sampling volume of up to 2.1 ml/day for rats with a body weight of around 250 g.


CONCLUSIONS
The new model increases throughput by avoiding the time required for preparative surgery, increases quality by allowing inter-animal comparison of major PK parameters as concentration time curves can be obtained from each animal, and reduces the number of animals required.
Mackie
Claire
C
Johnson & Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica N.V., Discovery ADME-Tox, Turnhoutseweg 30, 2340 Beerse, Belgium.
Wuyts
Koen
K
Haseldonckx
Marc
M
Blokland
Saskia
S
Gysemberg
Petra
P
Verhoeven
Iris
I
Timmerman
Philip
P
Nijsen
Marjoleen
M
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001800:Blood Specimen Collection / Q000379:methods*; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D006207:Half-Life; D006400:Hematocrit / Q000379:methods; D007275:Injections, Intravenous / Q000379:methods; D007601:Jugular Veins; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D012501:Saphenous Vein
D015507:Drugs, Investigational